Clinical Trials Logo

Systemic Lupus Erythematosus clinical trials

View clinical trials related to Systemic Lupus Erythematosus.

Filter by:

NCT ID: NCT02633163 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

Start date: October 26, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.

NCT ID: NCT02558517 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus

CORTICOLUP
Start date: January 2014
Phase: Phase 3
Study type: Interventional

Systemic Lupus (SLE) is a chronic disease for which long term treatments are warranted. The aim of this study was to study the possibility of corticosteroids interruption in patients with quiescent SLE treated since at least one year with 5 milligrams of predonisone per day.

NCT ID: NCT02465580 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus

Start date: June 2015
Phase: Phase 2
Study type: Interventional

Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (IL-2). In a previous small sample trail performed by the investigator's group, the investigators found that the Low-dose IL-2 was effective and well tolerated in active SLE, and the effect was associated with selective modulation of CD4+ T cell subsets. This clinical study will confirm the efficacy and safety of low dose IL-2 treatment in SLE. The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in SLE.The investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for Systemic lupus erythematosus by randomized controlled study (hrIL-2 (N = 30) versus placebo group (N = 30)).

NCT ID: NCT02450396 Recruiting - Clinical trials for Rheumatoid Arthritis

Pregnancy and Medically Assisted Conception in Rare Diseases

EGR2
Start date: June 2014
Phase:
Study type: Observational

Rare diseases frequently affect women of childbearing age. Pregnancy in these women has become less rare, but remains associated with high levels of complications. One obstacle to their optimal management during pregnancy is that there are no prospective studies of pregnancy during rare diseases and several connective tissue diseases. As a consequence, the management of these pregnancies is non-standardised in terms of treatment, monitoring (frequency of consultations, laboratory tests and ultrasound), and organisation of care. Moreover, although these women (all diseases combined) are frequently exposed to medications potentially incompatible with pregnancy, little is known about the frequency of these exposures and especially their consequences to mother and child. For these reasons, researchers and clinicians from different specialties created an interdisciplinary research group on pregnancy and rare diseases (GR2), intended to improve the management of these patients' pregnancies. Using a single computer server, the investigators plan to set up a large prospective study of pregnancies in patients with rare diseases: various forms of myositis, lupus, antiphospholipid syndrome, Sjogren syndrome, scleroderma, and inflammatory rheumatic diseases. The investigators objective is to analyse the complications of pregnancies in women with rare diseases and then to improve their management and their quality of life.

NCT ID: NCT02403115 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Prediction of Outcome of Lupus Nephritis

Start date: October 2014
Phase:
Study type: Observational

The purpose of this study is to clarify the mechanisms involved in the formation and glomerular deposition of immune complexes in lupus nephritis. The determination of an antibody pattern specific for systemic lupus erythematosus and lupus nephritis may also have a role in predicting disease progression in patients with systemic lupus erythematosus without renal impairment. As for the patients enrolled in the study, the determination of their antibody patterns may contribute to a more targeted and personalized treatment, allowing a prediction of disease progression and the introduction of early targeted treatments, in order to block the onset and/or progression of renal damage.

NCT ID: NCT02270970 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

BLAST
Start date: October 2014
Phase: Phase 4
Study type: Interventional

This will be an open label, non-randomized trial of belimumab in at least 20 subjects to test the feasibility of belimumab as a single agent and to capitalize on simplified background treatment regimens to determine immunologic differences between patients who do versus do not meet clinical response criteria.

NCT ID: NCT02037971 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus.

EFEXO
Start date: February 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of exercise training on improving sleep in patients with systemic lupus erythematosus.

NCT ID: NCT01892748 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.

Start date: September 2012
Phase: N/A
Study type: Interventional

The potential role of vitamin D on disease susceptibility, activity and severity has been considered for several autoimmune rheumatologic diseases include systemic lupus erythematosus (SLE) . Although, there are few studies of vitamin D supplementation in SLE patients, especially in Juvenile Onset Systemic Lupus Erythematosus (JoSLE). The objective of this study is to evaluate the effect of vitamin D supplementation (cholecalciferol 50.000 international units (IU)/week for 24 weeks) on disease activity (clinical and laboratory parameters), fatigue and bone mass.

NCT ID: NCT01863641 Recruiting - Clinical trials for Systemic Lupus Erythematosus

The Effect of Calcitriol on Progress and Activity of Lupus Nephritis

Start date: April 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether calcitriol is effective in the treatment of lupus nephritis.

NCT ID: NCT01741857 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This study will explore safety and efficacy of allogeneic umbilical cord (UC) derived mesenchymal stem cells transplantation (MSCT) to treat patients with active and refractory systemic lupus erythematosus (SLE) who have been resistant to multiple standard treatments. The underlying hypothesis is that the active SLE condition is caused by an abnormal immune homeostasis that can be restored by MSCT.